NanoViricides Inc. (NNVC)

[JG36]

Ebolacide2 - if it works - may let the company cut some corners in getting a revenue-generating product into the market - but isn't key to the long-term success or failure of NNVC.

If after testing Ebolacide2 gets sidelined, like so many other 'cides (due to the Ebola epidemic subsiding) then I agree, it will have little effect on the long term success or failure of NNVC. But suppose that Ebola is still raging after Ebolacide2 shows some clear evidence of efficacy in animals, so the decision is made to rush Ebolacide2 into human trials without going through the year or so of tox testing that would normally be required. Now we have a binary event. Ebolacide2 works in humans, NNVC goes up above $10 a share, and NNVC can issue more shares to fund Flucide development without too much pain to shareholders. OR... Ebolacide2 doesn't work in humans, NNVC goes below $2 a share, and NNVC has to severely dilute existing shareholders to keep the doors open.

Ebolacide2 is a gamble that may in fact have a lot to do with the long term success or failure of NNVC, even while we can agree that any real money made will come from Flucide.